← All stocks

Atara Biotherapeutics, Inc.

ATRA Net buying

CIK 0001604464 #4357 in the set updated 17 Sep 2026

Bought (1 mo)

$999.99K

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$40.88K

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$40.88K

1 of 1 sales

Net

+$959.11K

+$959.11K against sales at will

By person

16 insiders · 2 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Cherry Brian N

Director

$999.99K (1)

—

+$999.99K

166,486

1.66%

$1.60M

+334.5%

Nguyen AnhCo

President and CEO

—

$40.88K (1)

−$40.88K

132,775

1.32%

$1.27M

+67.8%

EcoR1 Capital, LLC entity

10% owner

—

1,552,000

15.46%

$14.90M

+48.6%

Adiumentum Capital Fund I LP entity

Director

—

1,209,395

12.05%

$11.61M

+6.7%

Panacea Innovation Ltd entity

10% owner

—

1,011,000

10.07%

$9.71M

−1.2%

Redmile Group, LLC entity

Director

—

636,852

6.34%

$6.11M

+44.2%

Touchon Pascal

Director

—

77,955

0.7766%

$748.37K

+11.2%

Hyllengren Eric J

Former EVP, CFO & COO

—

56,231

0.5602%

$539.82K

+127.1%

Grant-Huerta Yanina

Chief Accounting Officer

—

49,636

0.4945%

$476.51K

+25.1%

HEIDEN WILLIAM K

Director

—

34,188

0.3406%

$328.20K

+138.1%

Gallagher Carol Giltner

Director

—

33,012

0.3289%

$316.92K

+31.1%

Fust Matthew K

Director

—

30,188

0.3007%

$289.80K

+191.4%

Henrich Jill

EVP, Chief Regulatory Officer

—

18,679

0.1861%

$179.32K

−9.9%

Roncarolo Maria Grazia

Director

—

17,368

0.1730%

$166.73K

+82.1%

MALLIK AMEET

Director

—

16,928

0.1686%

$162.51K

+86.0%

Ciongoli Gregory Austin

Director

—

12,000

0.1195%

$115.20K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Cherry Brian N

4 Sep 2026

Director

Buy

104,166

$9.60

$999.99K

Nguyen AnhCo

17 Aug 2026

President and CEO

Sell

5,062

$8.08

$40.88K

What was left out

Form 4 filings counted 2

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 0

History held since 19 Sep 2016